Catherine M Viscoli

List of Publications by Year in Descending Order

212 papers	26,272 citations	57 h-index	161 g-index
234 ext. papers	33,362 ext. citations	10.8 avg, IF	7.31 L-index

#	Paper	IF	Citations
212	A Randomized Controlled Trial of the Hemodynamic Effects of Empagliflozin in Patients with Type 2 Diabetes at High Cardiovascular Risk (the SIMPLE Trial).. *Diabetes*, **2022**,	0.9	1
211	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes.. *EClinicalMedicine*, **2022**, 43, 101240	11.3	1
210	Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF.. *JACC: Heart Failure*, **2022**, 10, 104-118	7.9	0
209	Efficacy of Dapagliflozin in Black Versus White Patients With Heart Failure and Reduced Ejection Fraction.. *JACC: Heart Failure*, **2022**, 10, 52-64	7.9	1
208	Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial. *Diabetes, Obesity and Metabolism*, **2022**, 24, 135-141	6.7	6
207	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.. *JACC: Heart Failure*, **2022**, 10, 184-197	7.9	4
206	Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease.. *Diabetes Research and Clinical Practice*, **2022**, 109837	7.4	1
205	Relationship of Dapagliflozin With Serum Sodium: Findings From the DAPA-HF Trial.. *JACC: Heart Failure*, **2022**, 10, 306-318	7.9	1
204	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases.. *Journal of Diabetes and Its Complications*, **2021**, 36, 108101	3.2	2
203	Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. *Lancet Diabetes and Endocrinology,the* , **2021**,	18.1	3
202	Dapagliflozin and atrial fibrillation in heart failure with reduced ejection fraction: insights from DAPA-HF. *European Journal of Heart Failure*, **2021**,	12.3	5
201	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to N-Terminal Pro-B-Type Natriuretic Peptide: Insights From the DAPA-HF Trial. *Circulation: Heart Failure*, **2021**, CIRCHEARTFAILURE121008837	7.6	2
200	Rationale and Design of a Cluster-Randomized Pragmatic Trial Aimed at Improving Use of Guideline Directed Medical Therapy in Outpatients with Heart Failure: PRagmatic Trial Of Messaging to Providers about Treatment of Heart Failure (PROMPT-HF). *American Heart Journal*, **2021**, 244, 107-107	4.9	2
199	Comprehensive Genomic Characterization of A Case of Granular Cell Tumor of the Posterior Pituitary Gland: A Case Report.. *Frontiers in Endocrinology*, **2021**, 12, 762095	5.7	0
198	Dapagliflozin and the Incidence of Type 2 Diabetes in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis From DAPA-HF. *Diabetes Care*, **2021**, 44, 586-594	14.6	24
197	Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. *ESC Heart Failure*, **2021**,	3.7	5
196	Effect of empagliflozin on myocardial structure and function in patients with type 2 diabetes at high cardiovascular risk: the SIMPLE randomized clinical trial. *International Journal of Cardiovascular Imaging*, **2021**, 1	2.5	1

195	Effect of dapagliflozin on anaemia in DAPA-HF. *European Journal of Heart Failure*, **2021**, 23, 617-628	12.3	14
194	A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. *European Cardiology Review*, **2021**, 16, e11	3.9	1
193	Dapagliflozin effects on lung fluid volumes in patients with heart failure and reduced ejection fraction: Results from the DEFINE-HF trial. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1426-1430	6.7	5
192	Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. *European Journal of Heart Failure*, **2021**, 23, 601-613	12.3	14
191	Differences in glycemic control between the treatment arms in cardiovascular outcome trials of type 2 diabetes medications do not explain cardiovascular benefits. *Journal of Pharmaceutical Policy and Practice*, **2021**, 14, 35	3.2	
190	Dapagliflozin in HFrEF Patients Treated With Mineralocorticoid Receptor Antagonists: An Analysis of DAPA-HF. *JACC: Heart Failure*, **2021**, 9, 254-264	7.9	23
189	Response to Comment on Neeland et al. The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. Diabetes Care 2020;43:3007-3015. *Diabetes Care*, **2021**, 44, e137-e138	14.6	
188	Use of diuretics and outcomes in patients with type 2 diabetes: findings from the EMPA-REG OUTCOME trial. *European Journal of Heart Failure*, **2021**, 23, 1085-1093	12.3	9
187	Dapagliflozin and Recurrent Heart Failure Hospitalizations in Heart Failure With Reduced Ejection Fraction: An Analysis of DAPA-HF. *Circulation*, **2021**, 143, 1962-1972	16.7	13
186	A Single Virtual Consult Reduces Severe Hyperglycemia in Patients Admitted with COVID19 Infection. *Journal of the Endocrine Society*, **2021**, 5, A335-A335	0.4	78
185	Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction. *JAMA Cardiology*, **2021**, 6, 499-507	16.2	35
184	Extreme High Insulin Requirements in Two Non-Diabetic Patients Following Cardiac Transplantation. *Journal of the Endocrine Society*, **2021**, 5, A383-A383	0.4	78
183	Acute Myeloid Leukemia Leading to Central Diabetes Insipidus. *Journal of the Endocrine Society*, **2021**, 5, A570-A571	0.4	78
182	Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial. *European Journal of Heart Failure*, **2021**, 23, 1217-1225	12.3	39
181	Time to cardiovascular benefits of empagliflozin: a post hoc observation from the EMPA-REG OUTCOME trial. *ESC Heart Failure*, **2021**, 8, 2603-2607	3.7	4
180	Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial. *JAMA Cardiology*, **2021**, 6, 1298-1305	16.2	2
179	Empagliflozin treatment effects across categories of baseline HbA1c, body weight and blood pressure as an add-on to metformin in patients with type 2 diabetes. *Diabetes, Obesity and Metabolism*, **2021**, 23, 425-433	6.7	7
178	Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF. *Circulation*, **2021**, 143, 298-309	16.7	69

177	Characterization and implications of the initial estimated glomerular filtration rate ‘dip’ upon sodium-glucose cotransporter-2 inhibition with empagliflozin in the EMPA-REG OUTCOME trial. *Kidney International*, **2021**, 99, 750-762	9.9	33
176	Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort. *Diabetes Care*, **2021**, 44, 340-349	14.6	3
175	Sporadic adamantinomatous craniopharyngioma with double-hit somatic APC mutations. *Neuro-Oncology Advances*, **2021**, 3, vdab124	0.9	1
174	Effects of dapagliflozin in heart failure with reduced ejection fraction and chronic obstructive pulmonary disease: an analysis of DAPA-HF. *European Journal of Heart Failure*, **2021**, 23, 632-643	12.3	8
173	Impact of polyvascular disease with and without co-existent kidney dysfunction on cardiovascular outcomes in diabetes: A post hoc analysis of EMPA-REG OUTCOME. *Diabetes, Obesity and Metabolism*, **2021**, 23, 1173-1181	6.7	4
172	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index. *European Journal of Heart Failure*, **2021**, 23, 1662-1672	12.3	6
171	Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes. *New England Journal of Medicine*, **2021**, 385, 669-670	59.2	
170	Empagliflozin in Heart Failure With Predicted Preserved Versus Reduced Ejection Fraction: Data From the EMPA-REG OUTCOME Trial. *Journal of Cardiac Failure*, **2021**, 27, 888-895	3.3	4
169	Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF. *European Heart Journal*, **2021**, 42, 3727-3738	9.5	22
168	Somatic NF1 mutations in pituitary adenomas: Report of two cases. *Cancer Genetics*, **2021**, 256-257, 26-30	2.3	
167	Lessons Learned From Major Clinical Outcomes Trials Involving Sodium-Glucose Cotransporter 2 Inhibitors. *Diabetes Spectrum*, **2021**, 34, 235-242	1.9	
166	Effects of empagliflozin on insulin initiation or intensification in patients with type 2 diabetes and cardiovascular disease: Findings from the EMPA-REG OUTCOME trial. *Diabetes, Obesity and Metabolism*, **2021**, 23, 2775-2784	6.7	2
165	Adherence to study drug in a stroke prevention trial"?>. *Journal of Stroke and Cerebrovascular Diseases*, **2020**, 29, 105048	2.8	1
164	Patient Characteristics, Clinical Outcomes, and Effect of Dapagliflozin in Relation to Duration of Heart Failure: Is It Ever Too Late to Start a New Therapy?. *Circulation: Heart Failure*, **2020**, 13, e007879	7.6	7
163	Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series. *ESC Heart Failure*, **2020**, 7, 1966-1971	3.7	13
162	Empagliflozin in Heart Failure: Diuretic and Cardiorenal Effects. *Circulation*, **2020**, 142, 1028-1039	16.7	105
161	Efficacy and safety of sodium-glucose co-transporter 2 inhibition according to left ventricular ejection fraction in DAPA-HF. *European Journal of Heart Failure*, **2020**, 22, 1247-1258	12.3	19
160	Cardiovascular Benefit of Empagliflozin Across the Spectrum of Cardiovascular Risk Factor Control in the EMPA-REG OUTCOME Trial. *Journal of Clinical Endocrinology and Metabolism*, **2020**, 105,	5.6	8

159	Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications. *Cardiovascular Endocrinology and Metabolism*, **2020**, 9, 56-59	2.5	7
158	Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. *JAMA - Journal of the American Medical Association*, **2020**, 323, 1353-1368	27.4	155
157	Effects of dapagliflozin in DAPA-HF according to background heart failure therapy. *European Heart Journal*, **2020**, 41, 2379-2392	9.5	80
156	Diagnosis and Management of pituitary disease with focus on the role of Magnetic Resonance Imaging. *Endocrine*, **2020**, 68, 489-501	4	3
155	Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial. *JACC: Heart Failure*, **2020**, 8, 811-818	7.9	44
154	Association between uric acid levels and cardio-renal outcomes and death in patients with type 2 diabetes: A subanalysis of EMPA-REG OUTCOME. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1207-1214	6.7	14
153	The authors reply. *Kidney International*, **2020**, 97, 213-214	9.9	
152	Empagliflozin reduces the risk of mortality and hospitalization for heart failure across Thrombolysis In Myocardial Infarction Risk Score for Heart Failure in Diabetes categories: Post hoc analysis of the EMPA-REG OUTCOME trial. *Diabetes, Obesity and Metabolism*, **2020**, 22, 1141-1150	6.7	9
151	MON-645 Association of Baseline Cardio-Metabolic Parameters on the Treatment Effects of Empagliflozin When Added to Metformin in Patients with T2D. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
150	SAT-258 Surprising Transformation of a Microprolactinoma to a Macroprolactinoma. *Journal of the Endocrine Society*, **2020**, 4,	0.4	78
149	131-LB: Empagliflozin Reduces the Total Burden of All-Cause Hospitalizations (ACH) and Mortality in EMPA-REG Outcome. *Diabetes*, **2020**, 69, 131-LB	0.9	1
148	Response to Comment on Flory et al. Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. Diabetes Care 2020;43:244-246. *Diabetes Care*, **2020**, 43, e159	14.6	
147	Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. *Diabetes Care*, **2020**, 43, 244-246	14.6	16
146	Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age: Insights From DAPA-HF. *Circulation*, **2020**, 141, 100-111	16.7	68
145	Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction: Results From the DAPA-HF Trial. *Circulation*, **2020**, 141, 90-99	16.7	130
144	Efficacy of empagliflozin on heart failure and renal outcomes in patients with atrial fibrillation: data from the EMPA-REG OUTCOME trial. *European Journal of Heart Failure*, **2020**, 22, 126-135	12.3	30
143	Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?. *Diabetes, Obesity and Metabolism*, **2020**, 22, 631-639	6.7	39
142	The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial. *Diabetes Care*, **2020**, 43, 3007-3015	14.6	13

141	Dapagliflozin and Diuretic Use in Patients With Heart Failure and Reduced Ejection Fraction in DAPA-HF. *Circulation*, **2020**, 142, 1040-1054	16.7	52
140	Metabolic syndrome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a post hoc analyses of the EMPA-REG OUTCOME trial. *Cardiovascular Diabetology*, **2020**, 19, 200	8.7	5
139	Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 949-959	18.1	14
138	Consistent effects of empagliflozin on cardiovascular and kidney outcomes irrespective of diabetic kidney disease categories: Insights from the EMPA-REG OUTCOME trial. *Diabetes, Obesity and Metabolism*, **2020**, 22, 2335-2347	6.7	7
137	Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy. *Diabetes Care*, **2020**, 43, 2878-2881	14.6	8
136	Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF. *Circulation*, **2020**, 142, 1623-1632	16.7	20
135	Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF). *European Heart Journal*, **2020**, 41, 3402-3418	9.5	40
134	Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME trial. *European Heart Journal*, **2020**, 41, 209-217	9.5	20
133	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. *New England Journal of Medicine*, **2019**, 381, 1995-2008	59.2	2021
132	Diabetes prevention and cardiovascular complications. *Diabetologia*, **2019**, 62, 2161-2162	10.3	4
131	Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial. *Circulation*, **2019**, 140, 1463-1476	16.7	163
130	Efficacy and safety of empagliflozin in older patients in the EMPA-REG OUTCOME trial. *Age and Ageing*, **2019**, 48, 859-866	3	34
129	FDA guidance on antihyperglyacemic therapies for type 2 diabetes: One decade later. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1073-1078	6.7	27
128	Retinopathy Outcomes With Empagliflozin Versus Placebo in the EMPA-REG OUTCOME Trial. *Diabetes Care*, **2019**, 42, e53-e55	14.6	13
127	Pioglitazone: The forgotten, cost-effective cardioprotective drug for type 2 diabetes. *Diabetes and Vascular Disease Research*, **2019**, 16, 133-143	3.3	63
126	Understanding Contemporary Use of Thiazolidinediones. *Circulation: Heart Failure*, **2019**, 12, e005855	7.6	19
125	Treating Heart Failure With Antihyperglycemic Medications: Is Now the Right Time?. *Circulation*, **2019**, 139, 2383-2385	16.7	
124	Evidence supports prediabetes treatment. *Science*, **2019**, 364, 341-342	33.3	16

123	A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). *European Journal of Heart Failure*, **2019**, 21, 665-675	12.3	145
122	Analysis from the EMPA-REG OUTCOME trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics. *Kidney International*, **2019**, 96, 489-504	9.9	47
121	Empagliflozin Is Associated With a Lower Risk of Post-Acute Heart Failure Rehospitalization and Mortality. *Circulation*, **2019**, 139, 1458-1460	16.7	34
120	An Error in An Old Paper Illustrates the Need for Data/Code Archives - Author response. *Journal of Clinical Epidemiology*, **2019**, 107, 129	5.7	
119	Pioglitazone Therapy in Patients With Stroke and Prediabetes: A Post Hoc Analysis of the IRIS Randomized Clinical Trial. *JAMA Neurology*, **2019**, 76, 526-535	17.2	42
118	The Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure (DAPA-HF) trial: baseline characteristics. *European Journal of Heart Failure*, **2019**, 21, 1402-1411	12.3	103
117	Glucose Control and the Effect of Empagliflozin on Kidney Outcomes in Type 2 Diabetes: An Analysis From the EMPA-REG OUTCOME Trial. *American Journal of Kidney Diseases*, **2019**, 74, 713-715	7.4	27
116	Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial). *BMJ Open*, **2019**, 9, e029098	3	3
115	Achievement of Guideline-Recommended Weight Loss Among Patients With Ischemic Stroke and Obesity. *Stroke*, **2019**, 50, 713-717	6.7	5
114	Reduction in albuminuria with dapagliflozin cannot be predicted by baseline clinical characteristics or changes in most other risk markers. *Diabetes, Obesity and Metabolism*, **2019**, 21, 720-725	6.7	10
113	Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. *Circulation*, **2019**, 139, 366-375	16.7	21
112	Composite cardiovascular risk factor target achievement and its predictors in US adults with diabetes: The Diabetes Collaborative Registry. *Diabetes, Obesity and Metabolism*, **2019**, 21, 1121-1127	6.7	25
111	Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial. *Circulation*, **2019**, 139, 1384-1395	16.7	115
110	Metabolic syndrome identifies normal weight insulin-resistant stroke patients at risk for recurrent vascular disease. *International Journal of Stroke*, **2019**, 14, 639-645	6.3	2
109	Hypoglycemia in type 2 diabetes: understanding patients and physicians knowledge and experience. *Endocrine*, **2018**, 60, 435-444	4	3
108	Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME trial. *European Heart Journal*, **2018**, 39, 363-370	9.5	171
107	Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease. *Endocrinology and Metabolism Clinics of North America*, **2018**, 47, 137-152	5.5	6
106	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Editors Expert Forum. *Diabetes Care*, **2018**, 41, 14-31	14.6	263

105	Renoprotective effects of sodium-glucose cotransporter-2 inhibitors. *Kidney International*, **2018**, 94, 26-39	9.9	160
104	Empagliflozin in women with type 2 diabetes and cardiovascular disease - an analysis of EMPA-REG OUTCOME . *Diabetologia*, **2018**, 61, 1522-1527	10.3	33
103	Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. *American Heart Journal*, **2018**, 202, 39-48	4.9	12
102	Distance from Home to Research Center: A Barrier to In-Person Visits but Not Treatment Adherence in a Stroke Trial. *Neuroepidemiology*, **2018**, 50, 137-143	5.4	5
101	Pioglitazone Prevents Stroke in Patients With a Recent Transient Ischemic Attack or Ischemic Stroke: A Planned Secondary Analysis of the IRIS Trial (Insulin Resistance Intervention After Stroke). *Circulation*, **2018**, 137, 455-463	16.7	32
100	Effects of pioglitazone on cognitive function in patients with a recent ischaemic stroke or TIA: a report from the IRIS trial. *Journal of Neurology, Neurosurgery and Psychiatry*, **2018**, 89, 21-27	5.5	4
99	Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease. *Circulation*, **2018**, 137, 119-129	16.7	252
98	Heart Failure After Ischemic Stroke or Transient Ischemic Attack in Insulin-Resistant Patients Without Diabetes Mellitus Treated With Pioglitazone. *Circulation*, **2018**, 138, 1210-1220	16.7	28
97	Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis. *Diabetes, Obesity and Metabolism*, **2018**, 20, 2140-2147	6.7	14
96	Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients. *New England Journal of Medicine*, **2018**, 379, 1107-1117	59.2	143
95	Assessing use of patient-focused pharmacotherapy in glycemic management through the Diabetes Collaborative Registry (DCR). *Journal of Diabetes and Its Complications*, **2018**, 32, 1035-1039	3.2	2
94	Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. *Diabetologia*, **2018**, 61, 2118-2125	10.3	79
93	Scoring System to Optimize Pioglitazone Therapy After Stroke Based on Fracture Risk. *Stroke*, **2018** , STROKEAHA118022745	6.7	6
92	How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial. *Diabetes Care*, **2018**, 41, 356-363	14.6	365
91	Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME. *Circulation*, **2018**, 137, 405-407	16.7	96
90	Empagliflozin and Assessment of Lower-Limb Amputations in the EMPA-REG OUTCOME Trial. *Diabetes Care*, **2018**, 41, e4-e5	14.6	116
89	Long-Term Benefit of Empagliflozin on Life Expectancy in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease. *Circulation*, **2018**, 138, 1599-1601	16.7	16
88	Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. *Lancet, The*, **2018**, 392, 2269-2279	40	46

87	Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control. *Circulation*, **2018**, 138, 1904-1907	16.7	75
86	Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial. *Journal of the American Society of Nephrology: JASN*, **2018**, 29, 2755-2769	12.7	81
85	Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME randomised trial. *Diabetologia*, **2018**, 61, 1712-1723	10.3	58
84	Levothyroxine pseudo-malabsorption: testing and treatment in the outpatient setting. *Therapeutic Advances in Endocrinology and Metabolism*, **2018**, 9, 217-222	4.5	4
83	Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR). *American Heart Journal*, **2018**, 203, 25-29	4.9	15
82	SP415EMPAGLIFLOZIN AND PROGRESSION OF CHRONIC KIDNEY DISEASE IN TYPE 2 DIABETES COMPLICATED BY NEPHROTIC-RANGE PROTEINURIA: INSIGHTS FROM THE EMPA-REG OUTCOME TRIAL. *Nephrology Dialysis Transplantation*, **2018**, 33, i487-i487	4.3	
81	Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus. *Circulation*, **2017**, 135, 1882-1893	16.7	42
80	A randomized clinical trial evaluating the efficacy and safety of the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in patients with type 2 diabetes inadequately controlled on metformin monotherapy. *Current Medical Research and Opinion*, **2017**, 33, 1853-1860	2.5	8
79	Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk. *Stroke*, **2017**, 48, 1218-1225	6.7	86
78	Response to Comment on Inzucchi et al. Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. Diabetes Care 2016;39:1684-1692. *Diabetes Care*, **2017**, 40, e47-e48	14.6	1
77	Targeting Pioglitazone Hydrochloride Therapy After Stroke or Transient Ischemic Attack According to Pretreatment Risk for Stroke or Myocardial Infarction. *JAMA Neurology*, **2017**, 74, 1319-1327	17.2	13
76	Response by Young et al to Letters Regarding Article, "Cardiac Outcomes After Ischemic Stroke or Transient Ischemic Attack: Effects of Pioglitazone in Patients With Insulin Resistance Without Diabetes Mellitus". *Circulation*, **2017**, 136, 1567-1568	16.7	
75	Bladder cancer in the EMPA-REG OUTCOME trial. *Diabetologia*, **2017**, 60, 2534-2535	10.3	18
74	Quality of Care of the Initial Patient Cohort of the Diabetes Collaborative Registry. *Journal of the American Heart Association*, **2017**, 6,	6	14
73	Real-world use and modeled impact of glucose-lowering therapies evaluated in recent cardiovascular outcomes trials: An NCDR Research to Practice project. *European Journal of Preventive Cardiology*, **2017**, 24, 1637-1645	3.9	73
72	Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes. *Diabetes Care*, **2017**, 40, 1128-1132	14.6	21
71	Metformin: clinical use in type 2 diabetes. *Diabetologia*, **2017**, 60, 1586-1593	10.3	170
70	Response by Zinman et al to Letter Regarding Article, "Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk". *Stroke*, **2017**, 48, e256-e257	6.7	

69	Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 610-621	18.1	217
68	Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013. *Diabetes Care*, **2017**, 40, 468-475	14.6	181
67	Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. *European Journal of Heart Failure*, **2017**, 19, 43-53	12.3	76
66	Pioglitazone and Risk for Bone Fracture: Safety Data From a Randomized Clinical Trial. *Journal of Clinical Endocrinology and Metabolism*, **2017**, 102, 914-922	5.6	46
65	Approach to diabetes management in patients with CVD. *Trends in Cardiovascular Medicine*, **2016**, 26, 165-79	6.9	28
64	Minimization of Hypoglycemia as an Adverse Event During Insulin Infusion: Further Refinement of the Yale Protocol. *Diabetes Technology and Therapeutics*, **2016**, 18, 480-6	8.1	13
63	Citizen Petition to the US Food and Drug Administration to Change Prescribing Guidelines: The Metformin Experience. *Circulation*, **2016**, 134, 1405-1408	16.7	24
62	Implications of the EMPA-REG Trial for Clinical Care and Research. *Current Diabetes Reports*, **2016**, 16, 131	5.6	4
61	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*, **2016**, 375, 1801-2	59.2	85
60	Taking care of volunteers in a stroke trial: a new assisted-management strategy. *Stroke and Vascular Neurology*, **2016**, 1, 108-114	9.1	1
59	Evaluating the Quality of Comprehensive Cardiometabolic Care for Patients With Type 2 Diabetes in the U.S.: The Diabetes Collaborative Registry. *Diabetes Care*, **2016**, 39, e99-e101	14.6	23
58	Response to Comment on American Diabetes Association. Approaches to Glycemic Treatment. Sec. 7. In Standards of Medical Care in Diabetes-2016. Diabetes Care 2016;39(Suppl. 1):S52-S59. *Diabetes Care*, **2016**, 39, e88-9	14.6	11
57	Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. *New England Journal of Medicine*, **2016**, 375, 323-34	59.2	1956
56	SGLT2 inhibitors in the management of type 2 diabetes. *Endocrine*, **2016**, 53, 364-72	4	47
55	Pioglitazone after Ischemic Stroke or Transient Ischemic Attack. *New England Journal of Medicine*, **2016**, 374, 1321-31	59.2	654
54	Current Therapies for the Medical Management of Diabetes. *Obstetrics and Gynecology*, **2016**, 127, 780-794	4.9	15
53	How to Use Type 2 Diabetes Treatments in Clinical Practice: Combination Therapies **2016**, 471-492		
52	A Diagnostic Score for Insulin Resistance in Nondiabetic Patients with Ischemic Stroke or Transient Ischemic Attack. *Journal of Stroke and Cerebrovascular Diseases*, **2016**, 25, 1705-1712	2.8	1

51	Improving Type 2 Diabetes Patient Health Outcomes with Individualized Continuing Medical Education for Primary Care. *Diabetes Therapy*, **2016**, 7, 473-81	3.6	3
50	Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease. *Diabetes Care*, **2016**, 39, 1684-92	14.6	43
49	The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone. *Journal of Diabetes*, **2016**, 8, 607-9	3.8	3
48	Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial. *American Heart Journal*, **2015**, 170, 753-759.e2	4.9	5
47	How well do glucose variability measures predict patient glycaemic outcomes during treatment intensification in type 2 diabetes?. *Diabetes Research and Clinical Practice*, **2015**, 108, 179-86	7.4	12
46	Recognition of incident diabetes mellitus during an acute myocardial infarction. *Circulation: Cardiovascular Quality and Outcomes*, **2015**, 8, 260-7	5.8	13
45	SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. *Diabetes and Vascular Disease Research*, **2015**, 12, 90-100	3.3	283
44	Response to Comments on Inzucchi et al. Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care	14.6	21
43	Sensitivity of Traditional and Risk-Based Glycemic Variability Measures to the Effect of Glucose-Lowering Treatment in Type 2 Diabetes Mellitus. *Journal of Diabetes Science and Technology*, **2015**, 9, 1227-35	4.1	12
42	Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. *New England Journal of Medicine*, **2015**, 373, 2117-28	59.2	6064
41	Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, **2015**, 38, 140-9	14.6	1906
40	Glycemic targets: what is the evidence?. *Medical Clinics of North America*, **2015**, 99, 47-67	7	10
39	Autonomic dysfunction independently predicts poor cardiovascular outcomes in asymptomatic individuals with type 2 diabetes in the DIAD study. *SAGE Open Medicine*, **2015**, 3, 2050312114568476	2.4	17
38	Hyperglycemia grand rounds: descriptive findings of outcomes from a continuing education intervention to improve glycemic control and prevent hypoglycemia in the hospital setting. *Hospital Practice (1995)*, **2015**, 43, 270-6	2.2	3
37	Metabolic Management during Critical Illness: Glycemic Control in the ICU. *Seminars in Respiratory and Critical Care Medicine*, **2015**, 36, 859-69	3.9	17
36	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia*, **2015**, 58, 429-42	10.3	496
35	The prevalence of undiagnosed diabetes mellitus and the association of baseline glycemic control on mortality in the intensive care unit: a prospective observational study. *Journal of Critical Care*, **2014**, 29, 1052-6	4	15
34	The reliability of in-hospital diagnoses of diabetes mellitus in the setting of an acute myocardial infarction. *BMJ Open Diabetes Research and Care*, **2014**, 2, e000046	4.5	7

33	Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. *American Heart Journal*, **2014**, 168, 823-9.e6	4.9	34
32	Litigation seeking access to data from ongoing clinical trials: a threat to clinical research. *JAMA Internal Medicine*, **2014**, 174, 1502-4	11.5	1
31	The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy. *Diabetes Care*, **2014**, 37, 1924-30	14.6	40
30	Rationale, design, and baseline characteristics of a randomized, placebo-controlled cardiovascular outcome trial of empagliflozin (EMPA-REG OUTCOME). *Cardiovascular Diabetology*, **2014**, 13, 102	8.7	153
29	Metformin in patients with type 2 diabetes and kidney disease: a systematic review. *JAMA - Journal of the American Medical Association*, **2014**, 312, 2668-75	27.4	355
28	National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. *JAMA Internal Medicine*, **2014**, 174, 1116-24	11.5	270
27	Decade-long trends in mortality among patients with and without diabetes mellitus at a major academic medical center. *JAMA Internal Medicine*, **2014**, 174, 1187-8	11.5	15
26	Using the glucometrics website to benchmark ICU glucose control before and after the NICE-SUGAR study. *Journal of Diabetes Science and Technology*, **2014**, 8, 918-22	4.1	6
25	Clitoral epidermoid cyst presenting as pseudoclitoromegaly of pregnancy. *AJP Reports*, **2013**, 3, 57-62	1.2	3
24	Effects on post-prandial glucose and AGE precursors from two initial insulin strategies in patients with type 2 diabetes uncontrolled by oral agents. *Journal of Diabetes and Its Complications*, **2012**, 26, 333-8	3.2	4
23	Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*, **2012**, 35, 1364-79	14.6	2713
22	Clinical practice. Diagnosis of diabetes. *New England Journal of Medicine*, **2012**, 367, 542-50	59.2	134
21	Chromium Picolinate for the Prevention of Type 2 Diabetes **2011**, 3, 34-40		1
20	New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. *Circulation*, **2008**, 117, 574-84	16.7	154
19	Metformin therapy in patients with type 2 diabetes complicated by heart failure. *American Heart Journal*, **2007**, 154, e45	4.9	7
18	Incretin enhancers and the evolution of antihyperglycemic therapy in type 2 diabetes. *Endocrinology and Metabolism Clinics of North America*, **2007**, 36 Suppl 2 Incretin, 2-17	5.5	
17	Clinical practice. Management of hyperglycemia in the hospital setting. *New England Journal of Medicine*, **2006**, 355, 1903-11	59.2	286
16	The prevention of type 2 diabetes mellitus. *Endocrinology and Metabolism Clinics of North America*, **2005**, 34, 199-219, viii	5.5	36

15	Treatment of diabetes in the elderly. Addressing its complexities in this high-risk group. *Postgraduate Medicine*, **2005**, 118, 19-26, 29	3.7	26
14	Estrogen therapy and risk of cognitive decline: results from the WomenÃ Estrogen for Stroke Trial (WEST). *American Journal of Obstetrics and Gynecology*, **2005**, 192, 387-93	6.4	75
13	Insulin-sensitizing antihyperglycemic drugs and mortality after acute myocardial infarction: insights from the National Heart Care Project. *Diabetes Care*, **2005**, 28, 1680-9	14.6	77
12	Management of hypercalcemia. Diagnostic workup, therapeutic options for hyperparathyroidism and other common causes. *Postgraduate Medicine*, **2004**, 115, 27-36	3.7	13
11	Type 2 Diabetes Mellitus and Insulin Resistance: Stroke Prevention and Management. *Current Treatment Options in Neurology*, **2004**, 6, 443-450	4.4	38
10	Diabetes mellitus in pregnancy. *Obstetrics and Gynecology Clinics of North America*, **2004**, 31, 907-33, xi-xii	3.3	31
9	Understanding hypercalcemia. Its metabolic basis, signs, and symptoms. *Postgraduate Medicine*, **2004**, 115, 69-70, 73-6	3.7	45
8	Metformin: new understandings, new uses. *Drugs*, **2003**, 63, 1879-94	12.1	233
7	Oral antihyperglycemic therapy for type 2 diabetes: scientific review. *JAMA - Journal of the American Medical Association*, **2002**, 287, 360-72	27.4	789
6	Type 2 diabetes therapy. A pathophysiologically based approach. *Postgraduate Medicine*, **2002**, 111, 83-4, 87-92, 95	3.7	4
5	Glycemic management of diabetes in the perioperative setting. *International Anesthesiology Clinics*, **2002**, 40, 77-93	0.6	6
4	The frequency of undiagnosed diabetes and impaired glucose tolerance in patients with idiopathic sensory neuropathy. *Muscle and Nerve*, **2001**, 24, 1229-31	3.4	198
3	Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. *Cancer*, **2001**, 91, 443-54	6.4	178
2	The stroke prognosis instrument II (SPI-II) : A clinical prediction instrument for patients with transient ischemia and nondisabling ischemic stroke. *Stroke*, **2000**, 31, 456-62	6.7	151
1	Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial. *Sleep and Breathing*,	3.1	0